Ferring Pharmaceuticals Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care
5/28/2013 8:24:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated that use of a controlled release misoprostol vaginal insert significantly reduced time to vaginal delivery compared to a dinoprostone vaginal insert.1
Help employers find you! Check out all the jobs and post your resume.
comments powered by